Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Construction will begin this year with the new capacity anticipated by 2025
Hampton joins PCC from Accord Healthcare, where he was the President and responsible for accelerating the firm's growth strategy
Establishes distribution center in top hub for international shipping
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Subscribe To Our Newsletter & Stay Updated
